Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis.

Jingzhong OuyangZhengzheng WangYuan Kun Feng YeYanzhao ZhouQingjun LiNanmu YangHaitao ZhaoHong ZhaoJinxue Zhou

Published in: Journal of hepatocellular carcinoma (2023)

Postoperative adjuvant lenvatinib plus PD-1 antibody significantly improved RFS in patients with HCC at high risks of recurrence with acceptable safeties.

Keyphrases

early stage
human health
free survival
patients undergoing
risk assessment
climate change